SIB-RT plus S-1 improves survival in elderly inoperable esophageal cancer
Combination therapy improves survival in older esophageal cancer patients
This phase III multicenter RCT compared simultaneous integrated boost radiotherapy plus oral S-1 (CRTCT) to radiotherapy alone in patients a…
Adding chemo to radiation boosts 5-year survival from 24% to 34% in older patients with inoperable esophageal cancer.
S-1 plus oxaliplatin consolidation shows low toxicity in stage II/III lower rectal cancer patients
First study reports SOX consolidation for lower rectal cancer
This Phase I study enrolled 12 patients with stage II/III lower rectal adenocarcinoma.
A small early trial found SOX chemotherapy was safe after radiation for lower rectal cancer, with surgery completed on time for all patients…
Case report describes sintilimab-associated toxic epidermal necrolysis in gastric carcinoma patient
Rare Skin Reaction Follows Successful Stomach Cancer Therapy
This case report details a patient with gastric carcinoma developing delayed-onset toxic epidermal necrolysis during neoadjuvant sintilimab …
A new case shows a common stomach cancer drug can cause dangerous skin reactions even after surgery.
Subcutaneous PEG-rhG-CSF reduced grade ≥3 neutropenia and CIN in GI cancer patients receiving oral chemotherapy
New Shot Cuts Severe Low White Blood Cell Risk
This prospective, single-center, open-label, exploratory, non-randomized controlled study evaluated subcutaneous PEG-rhG-CSF in 43 gastroint…
A simple shot given before chemotherapy could keep your body's infection-fighting cells strong when taking oral cancer pills.
Serplulimab with FOLFOX showed disease control in AFP-producing gastric adenocarcinoma with liver metastases
Rare Stomach Cancer Shrinks After New Combo Treatment
This case report and literature review describes a 67-year-old man with AFP-producing gastric adenocarcinoma and liver metastases treated wi…
A rare stomach cancer that spread to the liver shrank dramatically when doctors combined standard chemotherapy with a newer immune-boosting …